Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO 2023-10-24 08:41
Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting 2023-08-10 09:02
Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting 2023-06-06 09:06
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE 2023-05-09 10:00
Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 2023-04-17 14:01
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003 2023-03-16 09:58
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023 2023-03-15 10:06
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022 2022-12-12 15:51
Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022 2022-12-12 15:00
Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 2022-12-12 10:33
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology 2022-11-22 09:18
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022 2022-09-14 09:11
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022 2022-09-14 09:04
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ) 2022-09-14 09:01
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer 2022-08-09 11:18
Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052 2022-06-14 08:58
Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO 2022-06-06 10:49
Research Updates on KN046 Presented at 2022 ASCO 2022-06-06 09:47
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:36
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:35
1 2 3 4